-
-
-
-
-
-
-
Recursion Pharmaceuticals, Inc. (RXRX) Tops Q1 EPS by 4c, offers outlook
-
-
-
-
-
-
-
Recursion Pharmaceuticals, Inc. (RXRX) Tops Q3 EPS by 1c
-
-
-
-
-
-
-
Recursion Pharmaceuticals (RXRX) to cut 20% staff
-
-
-
-
-
-
-
Recursion Pharmaceuticals (RXRX) Appoints Namandjé Bumpus and Elaine Sun to its Board
-
-
-
-
-
-
-
Key takeaways from the 2024 BofA AI Conference
-
-
-
-
-
-
-
Recursion Pharmaceuticals (RXRX) Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphom
-
-
-
-
-
-
-
Recursion Pharmaceuticals (RXRX) to Merge with Exscientia (EXAI)
-
479,047 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


